# GSK4532990 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/gsk4532990

> The next catalyst for GSK4532990, sponsored by GSK plc (GSK), is its topline data readout, Nov 2027 to Feb 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | GSK4532990 |
| Codes | GSK4532990 |
| Sponsor | GSK plc (GSK) https://sec-api.dev/companies/gsk/catalysts |
| Indications | [Liver Diseases, Alcoholic](https://sec-api.dev/indications/liver-diseases-alcoholic), Nonalcoholic Fatty Liver Disease, [Non-alcoholic Fatty Liver Disease](https://sec-api.dev/indications/non-alcoholic-fatty-liver-disease) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### September 23, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Non-alcoholic Fatty Liver Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06104319 (Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-23 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-10-27." https://clinicaltrials.gov/study/NCT06104319

### January 31, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Nonalcoholic Fatty Liver Disease; Non-alcoholic Fatty Liver Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05583344 (Phase 2b Study of GSK4532990 in Adults With NASH): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-01-31 (ACTUAL); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT05583344

### October 27, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 2. Indication: Non-alcoholic Fatty Liver Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06104319 (Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-23 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-10-27." https://clinicaltrials.gov/study/NCT06104319?tab=results

### Nov 2027 to Feb 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Liver Diseases, Alcoholic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06613698 (A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-26 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT06613698

### November 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Liver Diseases, Alcoholic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06613698 (A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-26 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT06613698

## Same indication

- [Efimosfermin alfa](https://sec-api.dev/pdufa/efimosfermin-alfa) (GSK)
- [Efinopegdutide](https://sec-api.dev/pdufa/efinopegdutide) (MRK)

Calendar months: [November 2027](https://sec-api.dev/fda-calendar/2027-11)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/gsk4532990.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "GSK4532990 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/gsk4532990

```bibtex
@misc{secapidev_pdufa_gsk4532990_20261116,
  title        = {GSK4532990 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/gsk4532990}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_gsk4532990_20261116","title":"GSK4532990 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/gsk4532990","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
